<p>Biogen misses out on a huge deal that Novartis completed with AveXis. Plus, Incyte's phase 3 implosion, and what it means for immuno-oncology more broadly.</p>

Biogen misses out on a huge deal that Novartis completed with AveXis. Plus, Incyte's phase 3 implosion, and what it means for immuno-oncology more broadly.

Healthcare: What Was Biogen Thinking?

Healthcare, technology, energy, consumer goods, and more. Every day, Motley Fool analysts break down a specific industry and the stocks making headlines. Questions? Comments? Email us at IndustryFocus@fool.com.

Share Healthcare: What Was Biogen Thinking?

Sign up to save your podcasts

Healthcare: What Was Biogen Thinking?

Healthcare: What Was Biogen Thinking?

More shows like Industry Focus

Motley Fool Money

Motley Fool Answers

Rule Breaker Investing

MarketFoolery